NeoStem, Inc. NBS
("NeoStem" or the "Company"), a leader in the emerging cellular therapy
industry, today announced that it has been awarded the second year of a two
year grant totaling $595,252 for the "Development of Human, Autologous,
Pluripotent Very Small Embryonic Like (VSELs) Stem Cells as a Countermeasure
to Radiation Threat", Grant Number 5R43AI098325-02 from the National Institute
of Allergy and Infectious Diseases (NIAID), a division of the National
Institutes of Health (NIH). This peer reviewed grant was awarded to support
research to be headed by Denis O. Rodgerson, Ph.D., Director of Stem Cell
Science for NeoStem and Mariusz Ratajczak, M.D., Ph.D., who is the head of the
Stem Cell Biology Program at the James Graham Brown Cancer Center at the
University of Louisville and co-inventor of VSEL^TM Technology.
This award funds studies to investigate the potential of very small
embryonic-like stem cells as a countermeasure to radiological and nuclear
threat. The product candidate, which is an autologous stem cell therapy
derived from the patient's own stem cells, will be developed to rescue
patients who have been exposed to radiation due to nuclear accident or
terrorist threat and to treat cancer patients who have undergone radiation
therapy and who consequently have compromised immune systems. The award
included $295,252 for the first year and $300,000 for the second year of the
project.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in